CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
CohBar Inc (NASDAQ:CWBR) announced topline results from the Phase 1a/1b study of CB4211 for nonalcoholic steatohepatitis (NASH) and obesity. The study…
WBB Securities Upgrades CohBar to Buy, Announces $5 Price Target
WBB Securities analyst Steve Brozak upgrades CohBar (NASDAQ:CWBR) from Speculative Buy to Buy and announces $5 price target.
22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for NASH and obesity met its primary endpoint. The company also released Q2 results.
CohBar Q2 EPS $(0.08) Misses $(0.06) Estimate
CohBar (NASDAQ:CWBR) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 11.11 percent increase over losses of $(0.09) per share from the same
CohBar Reports Topline Results From Phase 1a/1b Study Of CB4211 For NASH, Obseity
CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced topline results from the multi-center,
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
